Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

14.04.2015: WILEX publishes Half-yearly Financial ReportWILEX AG today published its financial report on the first six months of 2015. The focus in these first half-year was on the research activities of its subsidiary Heidelberg Pharma GmbH and the funding of WILEX AG. ....More




Seite gelesen: 326887 | Heute: 138